Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    250 result(s) found for: Lymphoid cells. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003038-17 Sponsor Protocol Number: CART19-BE-02 Start Date*: 2020-09-18
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
    Full Title: Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity...
    Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10060555 Acute lymphoid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005818-10 Sponsor Protocol Number: AGMT_MALT-2 Start Date*: 2012-05-02
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001465-24 Sponsor Protocol Number: GC-LTFU-001 Start Date*: 2018-02-26
    Sponsor Name:Celgene Corporation
    Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
    Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025631 Malignant lymphoid neoplasm NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001101-52 Sponsor Protocol Number: CART19-BE-03Ped Start Date*: 2022-11-07
    Sponsor Name:Fundació Privada per a la Recerca i la Docència Sant Joan de Déu
    Full Title: Phase 2 study of the infusion of autologous, differentiated, peripheral blood T-cells expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3...
    Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10060555 Acute lymphoid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000297-38 Sponsor Protocol Number: CL1-68587-003 Start Date*: 2016-06-22
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
    Medical condition: Advanced lymphoid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060390 Leukaemia lymphoblastic acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005399-12 Sponsor Protocol Number: DKMS-16-01 Start Date*: 2017-08-02
    Sponsor Name:DKMS gemeinnützige GmbH
    Full Title: A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor
    Medical condition: Patients with high-risk AML, ALL or MDS which have to undergo allogenic transplantaion.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024349 Leukemia myeloid LLT
    20.0 100000004864 10024337 Leukemia lymphatic LLT
    20.0 100000004864 10068361 MDS LLT
    20.1 100000004864 10024330 Leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003185-26 Sponsor Protocol Number: CIK 2 Start Date*: 2009-04-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation
    Medical condition:  Patients with haematologic malignancies (excluding CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002971-42 Sponsor Protocol Number: PEG-HSR Start Date*: 2006-06-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.
    Medical condition: patients affected by linphoproliferative pathologies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005913-40 Sponsor Protocol Number: Treo TM Start Date*: 2006-01-17
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassem...
    Medical condition: Thalassemia Major
    Disease: Version SOC Term Classification Code Term Level
    6.1 10005329 SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002761-35 Sponsor Protocol Number: LAL1811 Start Date*: 2012-11-14
    Sponsor Name:INCYTE Biosciences International Sarl
    Full Title: Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio mult...
    Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003912-28 Sponsor Protocol Number: ALL2620 Start Date*: 2021-01-28
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.
    Medical condition: Ph+ Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000296-24 Sponsor Protocol Number: CL1-68587-002 Start Date*: 2017-10-20
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto...
    Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006862-27 Sponsor Protocol Number: CIK Start Date*: 2005-05-30
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Infusion of Cytokine Induced Killer (CIK) cells in patients relapsing after allogeneic stem cell transplantation
    Medical condition: Patients with hematologic malignancies (excluding CML) with a hematologic or molecular relapse after allogeneic transplantation (at least 60 days should have elapsed since transplant).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002972-29 Sponsor Protocol Number: CART19-BE-01 Start Date*: 2017-05-16
    Sponsor Name:IDIBAPS
    Full Title: Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (...
    Medical condition: Patients with leukemia or lymphoma refractory to therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008957 Chronic lymphatic leukemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000843 Acute lymphatic leukemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002343-14 Sponsor Protocol Number: RAG1-2019-01 Start Date*: 2020-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY
    Medical condition: Patients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019119-39 Sponsor Protocol Number: GIMEMALAL1509 Start Date*: 2011-05-16
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients
    Medical condition: De Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003574-28 Sponsor Protocol Number: THYTECH1-2018-005 Start Date*: 2019-11-26
    Sponsor Name:Rafael Correa Rocha
    Full Title: Phase I / II clinical trial, randomized, exploratory and prospective to evaluate the safety and efficacy of the transfusion of autologous TREG cells obtained from thymic tissue in the prevention of...
    Medical condition: To evaluate the efficacy in the prevention of the rejection of the transfusion of autologous thyTreg cells in children transplanted from the heart
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002517-36 Sponsor Protocol Number: CA180-015 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib...
    Medical condition: Lympohid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006520-19 Sponsor Protocol Number: MT103-202 Start Date*: 2007-10-11
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of pos...
    Medical condition: Patients with minimal residual disease (MRD) of positive B-precursor acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001937-16 Sponsor Protocol Number: AUTO1-AL1 Start Date*: 2020-02-17
    Sponsor Name:Autolus Limited
    Full Title: An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety and Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphob...
    Medical condition: Relapsed or refractory B cell acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 03:17:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA